Skip to content
NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE CAP

Herbalife Ltd. HLF

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.0B
▲ 0.9% YoY
$228.3M
▼ 10.2% YoY
$252.9M
▲ 54.8% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Herbalife Ltd. provides weight management, targeted nutrition, energy, sports and fitness, and outer nutrition products in 95 markets around the world. It uses a direct-selling business model to distribute and market its nutrition products to and through a global network of Members. As of December 31, 2025, it had sold 144 product types. As of December 31, 2025, it had approximately 8,500 employees, of which approximately 2,200 were located in the United States. Its manufacturing facilities, known as Herbalife Innovation and Manufacturing Facilities, include HIM Lake Forest and HIM Winston-Salem in the U.S., and HIM Suzhou in China. It also has contract manufacturers strategically located in countries including India, Italy, the U.S., Brazil, South Korea, Taiwan, Germany and the Netherlands. It maintains hub distribution centers in Los Angeles, Memphis and Venray, Netherlands, in addition to mid-size distribution centers in major countries.

Written from the business description in HERBALIFE LTD.'s annual report to the U.S. Securities and Exchange Commission, filed 18 February 2026. Every sentence was checked against that document before publication.

Growth

USD 5.0B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 5.0 · Net income 0.2
2.5B5.0B
2008201120142017202020232025
Compound annual growth
−1.1%
−1.9%
+1.2%
+4.2%
−10.8%
−9.3%
−3.9%
−1.6%
−12.0%
−4.5%
−25.7%
−61.8%
−61.1%
−6.8%
−19.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −1.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

5 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 9.5% · Net 4.5%
5%10%15%
200820162025
ROE
FY2013 · ROE 111.4%
50%100%
200820162025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: 29%.

Cash & shareholders

USD 8.2M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 252.9
250.0M500.0M
200820162025
Net buybacks $B Dividends $B
FY2025 · Dividends · · Net buybacks 0.0
0.5B1.0BDividendsNet buybacks
2008201120142017202020232025

USD 8.2M in buybacks — 4% of the year's profit went back to shareholders.

Total assetsUSD 2.8B
EquityUSD -515.1M
CashUSD 353.1M
Gross debtUSD 2.0B
Net debtUSD 1.6B
Current ratio1.13×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
HLF, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B5.05.05.15.25.85.54.94.94.44.54.55.04.84.13.52.72.32.4
Operating income $B0.50.40.40.50.70.60.60.70.60.50.60.50.70.70.60.40.30.3
EBITDA $B0.60.50.40.60.80.70.60.80.70.50.70.60.80.70.60.5◌◌
Income tax $B0.0−0.10.10.10.10.10.10.20.30.10.10.10.20.20.10.10.10.1
Net income $B0.20.30.10.30.40.40.30.30.20.30.30.30.50.50.40.30.20.2
Free cash flow $B0.30.20.20.20.30.50.40.60.50.20.50.30.60.40.40.30.20.2
EPS, diluted $2.202.501.423.234.132.772.201.981.291.513.973.404.913.943.322.321.613.36
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌0.301.201.200.730.450.400.80
Payout %———————000010232921182423
ROE %————————————111.498.381.271.068.691.5
Shares out B0.100.100.100.100.100.120.140.140.080.090.090.090.100.110.120.06◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. One check was skipped: EPS is not tagged before 2008. One check was skipped: revenue is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries
Listed onNYSE
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image